Amplipreptaq man

Manufactured by Roche

Sourced in Germany

The AmpliprepTaq-Man is a laboratory instrument designed for automated nucleic acid extraction and real-time PCR amplification. It provides a standardized workflow for sample preparation and analysis.

Automatically generated - may contain errors

Lab products found in correlation

Rapid immunochromatographic hiv 1 2 test, by Abbott (2 mentions) Murex hiv antigen antibody combination elisa, by Abbott (2 mentions) Unigold, by Trinity Biotech (2 mentions) Abon hiv rapid test, by Abbott (2 mentions) Architect assay, by Abbott (1 mentions)

7 protocols using amplipreptaq man

HIV Diagnostic and Monitoring Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Sample collection and all analyses were performed in the APIN-supported laboratory at JUTH. The APIN-supported laboratory engages in external quality assurance with UK-NEQAS and the American College of Pathologists; received South African National Accreditation System (SANAS) accreditation in October of 2017. The HIV status of each participant was determined using the rapid immunochromatographic HIV-1/2 test (Abbott Diagnostics) and the Murex HIV antigen/antibody Combination ELISA (Abbott Diagnostics), according to the manufacturer’s instructions. A participant was considered HIV infected if he/she tested positive on the 2 tests, HIV negative if negative for both tests, and discordant if positive for only 1 test, in which case a third test (tiebreaker) was conducted. Participants’ CD4 count was determined via flow cytometry (Partec GmbH), according to the manufacturer’s instructions.
HIV RNA was determined using the Roche Ampliprep TaqMan (Roche Diagnostics), according to the manufacturer’s protocol. The laboratory parameters included in this analysis were those measured at baseline and 24, 48, 96, and 144 weeks of ART. Baseline clinical assessments or laboratory evaluations for ART naive patients were the closest measurements to, and up to 6 months before ART commencement in most cases or 0.5 months after the ART start date.

Agbaji O.O., Abah I.O., Ebonyi A.O., Gimba Z.M., Abene E.E., Gomerep S.S., Falang K.D., Anejo-Okopi J., Agaba P.A., Ugoagwu P.O., Agaba E.I., Imade G.E., Sagay A.S., Okonkwo P., Idoko J.A, & Kanki P.J. (2019). Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults. Journal of the International Association of Providers of AIDS Care, 18, 2325958218821963.

+ Open protocol

+ Expand

HIV Diagnostic and Monitoring Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Sample collection and all analyses were performed in the APIN-supported laboratory at JUTH. The APIN-supported laboratory engages in external quality assurance with UK-NEQAS and the American College of Pathologists; received South African National Accreditation System (SANAS) accreditation in October of 2017. The HIV status of each participant was determined using the rapid immunochromatographic HIV-1/2 test (Abbott Diagnostics) and the Murex HIV antigen/antibody Combination ELISA (Abbott Diagnostics), according to the manufacturer’s instructions. A participant was considered HIV infected if he/she tested positive on the 2 tests, HIV negative if negative for both tests, and discordant if positive for only 1 test, in which case a third test (tiebreaker) was conducted. Participants’ CD4 count was determined via flow cytometry (Partec GmbH), according to the manufacturer’s instructions.
HIV RNA was determined using the Roche Ampliprep Taq-Man (Roche Diagnostics), according to the manufacturer’s protocol. The laboratory parameters included in this analysis were those measured at baseline and 24, 48, 96, and 144 weeks of ART. Baseline clinical assessments or laboratory evaluations for ART naive patients were the closest measurements to, and up to 6 months before ART commencement in most cases or 0.5 months after the ART start date.

+ Open protocol

+ Expand

Home-Based HIV Testing Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

HIV testing was conducted in the home using blood obtained by finger-stick and tested using rapid serologic tests according to national guidelines (in Uganda Determine (Abbott Laboratories) followed by Statpak (Chembio Diagnostics) for confirmation of positive results and Unigold (Trinity Biotech) as a tie breaker, and in South Africa, ABON HIV Rapid test (Alere) and First Response HIV Test (Premier Medical Corporation Ltd) with HIV 1/2 Gold Screening Test (G-Ocean) as a tie breaker, when needed. Point-of-care CD4 testing (Alere, PIMA^™) was conducted in the home using a finger-stick specimen. Plasma was obtained in the home and transported to the reference laboratory for HIV viral load testing by polymerase chain reaction (Roche Taqman Ampliprep with a limit of detection of 20 copies/mL).
The study protocol received ethical approval from the University of Washington Human Subjects Division, the Ugandan National HIV/AIDS Research Committee, and the Human Sciences Research Council Research Ethics Committee.

Barnabas R.V., van Rooyen H., Tumwesigye E., Murnane P.M., Baeten J.M., Humphries H., Turyamureeba B., Joseph P., Krows M., Hughes J.P, & Celum C. (2014). Initiation of antiretroviral therapy and viral suppression after home HIV testing and counselling in KwaZulu-Natal, South Africa, and Mbarara district, Uganda: a prospective, observational intervention study. The lancet. HIV, 1(2), e68-e76.

+ Open protocol

+ Expand

HIV Testing and Viral Load Monitoring

Check if the same lab product or an alternative is used in the 5 most similar protocols

HIV testing was conducted using blood obtained by finger-stick and tested using rapid serologic tests according to national guidelines: in Uganda Determine (Abbott Laboratories) followed by Statpak (Chembio Diagnostics) for confirmation of positive results and Unigold (Trinity Biotech) as a tie breaker, and in South Africa, ABON HIV Rapid test (Alere) and First Response HIV Test (Premier Medical Corporation Ltd) with HIV 1/2 Gold Screening Test (G-Ocean) as a tie breaker. Point-of-care CD4 testing (Alere, PIMA^™) was conducted using a finger-stick specimen. Plasma was obtained via phlebotomy at the home or in the mobile van and transported to the reference laboratory for HIV viral load testing by polymerase chain reaction (Roche Taqman Ampliprep, with a limit of detection of 20 copies/mL).

Barnabas R.V., van Rooyen H., Tumwesigye E., Brantley J., Baeten J.M., van Heerden A., Turyamureeba B., Joseph P., Krows M., Thomas K.K., Schaafsma T.T., Hughes J.P, & Celum C. (2016). Uptake of antiretroviral therapy and male circumcision following community-based HIV testing linkage strategies versus referral: A randomized, multisite, open-label, individual trial in South Africa and Uganda. The lancet. HIV, 3(5), e212-e220.

+ Open protocol

+ Expand

HCV Genotyping and Viral Load

Check if the same lab product or an alternative is used in the 5 most similar protocols

Reverse hybridisation was used for HCV genotyping (Inno-LIPA II HCV Innogenetics SA Ghent, Belgium). Viral load (cut-off <15 IU/mL) was quantitatively measured in serum with the HCV AmpliprepTaq-Man, Roche Molecular System, at the same time as the ALT determination.

Ruiz-Extremera A., Pavón-Castillero E.J., Florido M., Muñoz de Rueda P., Muñoz-Gámez J.A., Casado J., Carazo A., Quiles R., Jiménez-Ruiz S.M., Gila A., Luna J.D., León J, & Salmerón J. (2017). Influence of HLA class I, HLA class II and KIRs on vertical transmission and chronicity of hepatitis C virus in children. PLoS ONE, 12(2), e0172527.

+ Open protocol

+ Expand

Early and Late Virologic Failure

Check if the same lab product or an alternative is used in the 5 most similar protocols

The main study outcome measure was virologic failure defined as plasma viral load above 1000 copies/mL after 6 to 12 months of ART initiation [37 ]. We obtained viral load data at baseline, 24 weeks, and 72 weeks of ART. HIV RNA was determined using the Roche Ampliprep TaqMan (Roche Diagnostics, GmbH, Germany). For the purpose of this study, early virologic failure was defined as having an HIV viral load of >1000 copies/mL after ≥6 months (24 weeks) of ART [26 , 37 ], while late virologic failure was defined as having an HIV viral load of >1000 copies/mL after ≥ 18 months (72 weeks) of ART.

Abah I.O., Ncube N.B., Bradley H.A., Agbaji O.O, & Kanki P. (2018). Antiretroviral Therapy-associated Adverse Drug Reactions and their Effects on Virologic Failure- A Retrospective Cohort Study in Nigeria. Current HIV Research, 16(6), 436-446.

+ Open protocol

+ Expand

Quantification of ALT, HBV DNA, HBsAg, and HBeAg

Check if the same lab product or an alternative is used in the 5 most similar protocols

ALT in patients’ blood was quantified using ADVIA (Siemens). HBV DNA was analyzed with AmpliPrep Taqman (Roche). HBsAg and HBeAg were measured by Architect assay (Abbott). These measurements were done by the Laboratory Medicine Program of Toronto General Hospital/University Health Network.

Nkongolo S., Mahamed D., Kuipery A., Sanchez Vasquez J.D., Kim S.C., Mehrotra A., Patel A., Hu C., McGilvray I., Feld J.J., Fung S., Chen D., Wallin J.J., Gaggar A., Janssen H.L, & Gehring A.J. (2023). Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cells. The Journal of Clinical Investigation, 133(1), e158903.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!